In spite of being several results of efficacy obtained by randomized controlled trials about new health technologies, evidences related to real effectiveness confirmed by head-to-head direct comparison should be needed in order to improve qualities of healthcare. The comparative effectiveness evaluation (CEE) as outcomes research have suggested as the important tool for developing evidence-based information to patients, clinicians, and other decision makers about which technologies are most effective for which patients under specific circumstances. Four major methods of outcomes research are applied as systematic reviews and meta-analyses, cohort studies using registries, linkage of large databases, and pragmatic clinical trials. Through activating the CEE, the best and most effective technologies should be adopted rapidly in routine clinical practices. 
1972
Most patients felt better when exercised while taking alprenolol but there was no significant difference in the frequency of angina or ischaemic changes in the electrocardiogram during exercise with or without alprenolol.
Roland et al. 4) 1979 Beta-blockers showed little evidence of useful antiarrhythmic action in the dosage used, but increasing the dosage in suspected myocardial infarction is not practicable because of the risk of hypotension. The findings raise grave doubts about the value of studying arrhythmias to assess drugs intended to reduce mortality from myocardial infarction.
Pratt and Roberts 5) 1983 Authors recommend treatment of all patients who can tolerate beta blockade after acute MI, beginning in the late hospitalization phase and continuing for at least 2 years.
Baber and Lewis 6) 1983 It is unclear how long oral treatment should be maintained, nor is it known if stopping beta blockade increases the risk of sudden death or reinfarction.
Pedersen 7) 1983 Authors conclude that chronic treatment with timolol in survivors of acute myocardial infarction who can tolerate beta-adrenergic blockade is effective in reducing both total mortality and reinfarction over 33 months.
It is not clear how beta blockers reduce fatality, nor whether any one of this group of drugs is more effective than any other. Beta blockers produce adverse reactions and the risks of treatment have to be balanced against the benefits. It is not clear when treatment should begin, nor when it should stop. It is not possible to identify a sub-group of patients who should be given a beta blocker and another group in which treatment is unnecessary. 1984 Most patients should receive, routinely, a beta-blocker at the time of discharge from the hospital after infarction. Table 1 . Several conclusions of effect of a beta-adrenergic receptor blocker in myocardial infarction
Curtis et al. 14) OR Clinical research attempting to understand and improve the outcomes of illness and medical treatment by focusing on those outcomes important to patients and society
Institute of Medicine 15) CER Generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, or to improve the delivery of care Cost-utility analysis 
